Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1989 Oct;82(10):615–619. doi: 10.1177/014107688908201018

Neuroleptics and psychic indifference: a review.

D Healy 1
PMCID: PMC1292340  PMID: 2572700

Full text

PDF
615

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen H. A. Positive and negative symptoms and the thematic organisation of schizophrenic speech. Br J Psychiatry. 1984 Jun;144:611–617. doi: 10.1192/bjp.144.6.611. [DOI] [PubMed] [Google Scholar]
  2. Andén N. E., Butcher S. G., Corrodi H., Fuxe K., Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol. 1970;11(3):303–314. doi: 10.1016/0014-2999(70)90006-3. [DOI] [PubMed] [Google Scholar]
  3. Bannon M. J., Roth R. H. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev. 1983 Mar;35(1):53–68. [PubMed] [Google Scholar]
  4. Bell D. S. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry. 1973 Jul;29(1):35–40. doi: 10.1001/archpsyc.1973.04200010020003. [DOI] [PubMed] [Google Scholar]
  5. Beninger R. J. The role of dopamine in locomotor activity and learning. Brain Res. 1983 Oct;287(2):173–196. doi: 10.1016/0165-0173(83)90038-3. [DOI] [PubMed] [Google Scholar]
  6. Bowers M. B., Jr, Heninger G. R. Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment. Psychiatry Res. 1981 Jun;4(3):285–290. doi: 10.1016/0165-1781(81)90030-5. [DOI] [PubMed] [Google Scholar]
  7. CARLSSON A., LINDQVIST M. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh) 1963;20:140–144. doi: 10.1111/j.1600-0773.1963.tb01730.x. [DOI] [PubMed] [Google Scholar]
  8. Chiodo L. A., Bunney B. S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983 Aug;3(8):1607–1619. doi: 10.1523/JNEUROSCI.03-08-01607.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ciompi L. The natural history of schizophrenia in the long term. Br J Psychiatry. 1980 May;136:413–420. doi: 10.1192/bjp.136.5.413. [DOI] [PubMed] [Google Scholar]
  10. Crow T. J. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry. 1980 Oct;137:383–386. [PubMed] [Google Scholar]
  11. Crow T. J. The dopamine hypothesis survives, but there must be a way ahead. Br J Psychiatry. 1987 Oct;151:460–465. doi: 10.1192/bjp.151.4.460. [DOI] [PubMed] [Google Scholar]
  12. Frith C. D. The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med. 1987 Aug;17(3):631–648. doi: 10.1017/s0033291700025873. [DOI] [PubMed] [Google Scholar]
  13. Grau B. W., Mueser K. T. Measurement of negative symptoms. Schizophr Bull. 1986;12(1):7–11. doi: 10.1093/schbul/12.1.7. [DOI] [PubMed] [Google Scholar]
  14. Healy D. Rhythm and blues. Neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders. Psychopharmacology (Berl) 1987;93(3):271–285. doi: 10.1007/BF00187243. [DOI] [PubMed] [Google Scholar]
  15. Healy D., Williams J. M. Moods, misattributions and mania: an interaction of biological and psychological factors in the pathogenesis of mania. Psychiatr Dev. 1989 Spring;7(1):49–70. [PubMed] [Google Scholar]
  16. Hemsley D. R. What have cognitive deficits to do with schizophrenic symptoms? Br J Psychiatry. 1977 Feb;130:167–173. doi: 10.1192/bjp.130.2.167. [DOI] [PubMed] [Google Scholar]
  17. Huber G., Gross G., Schüttler R., Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6(4):592–605. doi: 10.1093/schbul/6.4.592. [DOI] [PubMed] [Google Scholar]
  18. Johnson D. A. Studies of depressive symptoms in schizophrenia. Br J Psychiatry. 1981 Aug;139:89–101. doi: 10.1192/bjp.139.2.89. [DOI] [PubMed] [Google Scholar]
  19. Johnstone E. C., Crow T. J., Frith C. D., Carney M. W., Price J. S. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978 Apr 22;1(8069):848–851. doi: 10.1016/s0140-6736(78)90193-9. [DOI] [PubMed] [Google Scholar]
  20. Joseph M. H., Frith C. D., Waddington J. L. Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model. Psychopharmacology (Berl) 1979 Jun 21;63(3):273–280. doi: 10.1007/BF00433561. [DOI] [PubMed] [Google Scholar]
  21. Kay S. R., Opler L. A. The positive-negative dimension in schizophrenia: its validity and significance. Psychiatr Dev. 1987 Summer;5(2):79–103. [PubMed] [Google Scholar]
  22. Kirkpatrick B., Johnson M., McGuire K., Fletcher R. H. Confounding and the dementia of schizophrenia. Psychiatry Res. 1986 Nov;19(3):225–231. doi: 10.1016/0165-1781(86)90101-0. [DOI] [PubMed] [Google Scholar]
  23. Kolakowska T., Williams A. O., Ardern M., Reveley M. A., Jambor K., Gelder M. G., Mandelbrote B. M. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry. 1985 Mar;146:229–239. doi: 10.1192/bjp.146.3.229. [DOI] [PubMed] [Google Scholar]
  24. Liddle P. F. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987 Aug;151:145–151. doi: 10.1192/bjp.151.2.145. [DOI] [PubMed] [Google Scholar]
  25. Lieberman J. A., Kane J. M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91(4):415–433. doi: 10.1007/BF00216006. [DOI] [PubMed] [Google Scholar]
  26. May P. R., Van Putten T., Yale C., Potepan P., Jenden D. J., Fairchild M. D., Goldstein M. J., Dixon W. J. Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis. 1976 Mar;162(3):177–183. doi: 10.1097/00005053-197603000-00004. [DOI] [PubMed] [Google Scholar]
  27. McKenna P. J. Disorders with overvalued ideas. Br J Psychiatry. 1984 Dec;145:579–585. doi: 10.1192/bjp.145.6.579. [DOI] [PubMed] [Google Scholar]
  28. McKenna P. J. Pathology, phenomenology and the dopamine hypothesis of schizophrenia. Br J Psychiatry. 1987 Sep;151:288–301. doi: 10.1192/bjp.151.3.288. [DOI] [PubMed] [Google Scholar]
  29. Meltzer H. Y., Stahl S. M. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2(1):19–76. doi: 10.1093/schbul/2.1.19. [DOI] [PubMed] [Google Scholar]
  30. Miller R. The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness. Psychopharmacology (Berl) 1987;92(4):405–415. doi: 10.1007/BF00176470. [DOI] [PubMed] [Google Scholar]
  31. Randrup A., Munkvad I. Role of catecholamines in the amphetamine excitatory response. Nature. 1966 Jul 30;211(5048):540–540. doi: 10.1038/211540a0. [DOI] [PubMed] [Google Scholar]
  32. Ridley R. M., Baker H. F. Is there a relationship between social isolation, cognitive inflexibility, and behavioral stereotypy? An analysis of the effects of amphetamine in the marmoset. Prog Clin Biol Res. 1983;131:101–135. [PubMed] [Google Scholar]
  33. Sacks M. H., Carpenter W. T., Jr, Strauss J. S. Recovery from delusions. Three phases documented by patient's interpretation of research procedures. Arch Gen Psychiatry. 1974 Jan;30(1):117–120. doi: 10.1001/archpsyc.1974.01760070093015. [DOI] [PubMed] [Google Scholar]
  34. Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980 Sep;32(3):229–313. [PubMed] [Google Scholar]
  35. Silverstone T. Dopamine in manic depressive illness. A pharmacological synthesis. J Affect Disord. 1985 May-Jun;8(3):225–231. doi: 10.1016/0165-0327(85)90020-5. [DOI] [PubMed] [Google Scholar]
  36. Snyder S. H. Neurotransmitters and CNS disease. Schizophrenia. Lancet. 1982 Oct 30;2(8305):970–974. doi: 10.1016/s0140-6736(82)90167-2. [DOI] [PubMed] [Google Scholar]
  37. Snyder S. H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976 Feb;133(2):197–202. doi: 10.1176/ajp.133.2.197. [DOI] [PubMed] [Google Scholar]
  38. Stevens J. R. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973 Aug;29(2):177–189. doi: 10.1001/archpsyc.1973.04200020023003. [DOI] [PubMed] [Google Scholar]
  39. Strauss J. S., Kokes R. F., Klorman R., Sacksteder J. L. Premorbid adjustment in schizophrenia: concepts, measures, and implications. Part I. The concept of premorbid adjustment. Schizophr Bull. 1977;3(2):182–185. doi: 10.1093/schbul/3.2.182. [DOI] [PubMed] [Google Scholar]
  40. Tantam D. Schizophrenic deterioration. 5. Br J Psychiatry. 1983 Jul;143:83–84. [PubMed] [Google Scholar]
  41. VENABLES P. H., WING J. K. Level of arousal and the subclassification of schizophrenia. Arch Gen Psychiatry. 1962 Aug;7:114–119. doi: 10.1001/archpsyc.1962.01720020038006. [DOI] [PubMed] [Google Scholar]
  42. Waddington J. L., Youssef H. A. Late onset involuntary movements in chronic schizophrenia: relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry. 1986 Nov;149:616–620. doi: 10.1192/bjp.149.5.616. [DOI] [PubMed] [Google Scholar]
  43. van Rossum J. M. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966 Apr;160(2):492–494. [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES